The Impact of First-Line Anti-Tubercular Drugs’ Pharmacokinetics on Treatment Outcome: A Systematic Review

Código QR

The Impact of First-Line Anti-Tubercular Drugs’ Pharmacokinetics on Treatment Outcome: A Systematic Review

Tesemma Sileshi,1,2 Esayas Tadesse,1 Eyasu Makonnen,2 Eleni Aklillu3 1Ambo University, Department of Pharmacy, Ambo, Ethiopia; 2Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia; 3Karolinska Institutet, Department of Laboratory Medicine, Stockholm, SwedenCorrespondence: Tesem...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sileshi T, Tadesse E, Makonnen E, Aklillu E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	tuberculosis pharmacokinetics treatment outcomes anti-tb drugs Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/ebb98947d17d4943a278d8d25172b0b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Impact of Protracted Displacement on Delay in the Diagnosis Associated with Treatment Outcomes: A Cross-Sectional Study in Internally Displaced Tuberculosis Patients of Pakistan
por: Farman Ullah Khan, et al.
Publicado: (2021)

Efficiency of various methods of injection of antituberculosis agents in young patients with destructive pulmonary tuberculosis
por: I. A. Morozov, et al.
Publicado: (2016)

Genitourinary Tuberculosis: A Comprehensive Review of a Neglected Manifestation in Low-Endemic Countries
por: Guglielmo Mantica, et al.
Publicado: (2021)

A Dual Marker for Monitoring MDR-TB Treatment: Host-Derived miRNAs and M. tuberculosis-Derived RNA Sequences in Serum
por: Claudia Carranza, et al.
Publicado: (2021)

Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure
por: Nathella Pavan Kumar, et al.
Publicado: (2021)

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
por: Gellért Balázs Karvaly, et al.
Publicado: (2021)

Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia
por: Molla Y, et al.
Publicado: (2021)

The Role of QuantiFERON-TB Gold Plus in Mycobacterium Tuberculosis Detection in a Severe HIV Immunocompromised Patient—Case Report
por: Florentina Dumitrescu, et al.
Publicado: (2021)

Tuberculosis and Human Immunodeficiency Virus Co-Infection and Associated Factors at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Four-Year Retrospective Study
por: Alemu A, et al.
Publicado: (2021)

Monitorización terapéutica de antibióticos: Nuevas metodologías: biosensores
por: Soto,Dagoberto, et al.
Publicado: (2015)

Self-nanoemulsfiying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis
por: Dou Y, et al.
Publicado: (2018)

The Capacity of <italic toggle="yes">Mycobacterium tuberculosis</italic> To Survive Iron Starvation Might Enable It To Persist in Iron-Deprived Microenvironments of Human Granulomas
por: Krishna Kurthkoti, et al.
Publicado: (2017)

Clinical Characteristics, Diagnosis, Treatment, and Mortality Rate of TB/COVID-19 Coinfectetd Patients: A Systematic Review
por: Maryam Koupaei, et al.
Publicado: (2021)

Nuevas perspectivas terapéuticas en tuberculosis
por: PEÑA M,CARLOS, et al.
Publicado: (2015)

INFLUENCE OF SEX DIFFERENCES ON PHARMACOKINETICS OF DRUGS WITHIN THE FRAMEWORK OF BIOEQUIVALENCE STUDIES OF GENERIC MEDICINAL PRODUCTS
por: D. P. Romodanovsky, et al.
Publicado: (2018)

Clinical Factors Associated with Cavitary Tuberculosis and Its Treatment Outcomes
por: Sun-Hyung Kim, et al.
Publicado: (2021)

Isolated gastric Tuberculosis: A case report
por: SH Semnani, et al.
Publicado: (2006)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
por: Roganović Maša, et al.
Publicado: (2021)

IMMUNOLOGIC PARAMETERS IN CHILDREN WITH TUBERCULOSIS INFECTION OF DIFFERENT ACTIVITY
por: N. V. Korneva, et al.
Publicado: (2014)

Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics
por: Chen R, et al.
Publicado: (2021)

Heterologous Production of 1-Tuberculosinyladenosine in <named-content content-type="genus-species">Mycobacterium kansasii</named-content> Models Pathoevolution towards the Transcellular Lifestyle of <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content>
por: Marwan Ghanem, et al.
Publicado: (2020)

Detección de la mutación S315T en el gen katg como estrategia para identificación de Mycobacterium tuberculosis resistente a isoniacida en un laboratorio de referencia
por: Romay,Zolay, et al.
Publicado: (2012)

Evaluación de dos pruebas comerciales para el serodiagnóstico de la tuberculosis pulmonar
por: D'Alessandro,Adriana, et al.
Publicado: (2008)

The influence of the site of drug administration on florfenicol pharmacokinetics in turkeys
por: A. Bello, et al.
Publicado: (2022)

Perceptions of Adolescents and Health Workers Towards Adolescents’ TB Diagnosis in Central Uganda: A Cross-Sectional Qualitative Study
por: Muttamba W, et al.
Publicado: (2021)

Estudio multicéntrico de factores pronósticos en adultos hospitalizados por neumonía adquirida en la comunidad
por: Gil D,Rodrigo, et al.
Publicado: (2006)

Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib
por: Tjandrawinata RR, et al.
Publicado: (2018)

Genomic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Strains From Patients in Kazakhstan
por: Asset Daniyarov, et al.
Publicado: (2021)

Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in vitro models to predict the impact of efflux transporters in the small intestine and blood–brain barrier
por: Yoshiki Hashimoto, et al.
Publicado: (2022)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Laura Molenaar-Kuijsten, et al.
Publicado: (2021)

Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment
por: Christopher G. Shield, et al.
Publicado: (2021)

MOLECULAR CHARACTERIZATION OF MYCOBACTERIUM TUBERCULOSIS STRAINS CIRCULATING IN THE URAL REGION, RUSSIA
por: T. V. Umpeleva, et al.
Publicado: (2014)

Aggregated Mycobacterium tuberculosis Enhances the Inflammatory Response
por: Hylton E. Rodel, et al.
Publicado: (2021)

An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
por: Tao Zhong, et al.
Publicado: (2021)

Development of nanoemulsion for efficient brain parenteral delivery of cefuroxime: designs, characterizations, and pharmacokinetics
por: Harun SN, et al.
Publicado: (2018)

Alginate-Capped Silver Nanoparticles as a Potent Anti-mycobacterial Agent Against Mycobacterium tuberculosis
por: Cheng-Cheung Chen, et al.
Publicado: (2021)

Mobile Health Intervention for Outpatient Treatment of Tuberculosis and HIV Infection
por: S. N. Zhdanova, et al.
Publicado: (2020)

PECULIARITIES OF BIOLOGICAL FEATURES OF MYCOBACTERIUM TUBERCULOSIS ON THE TERRITORY OF IRKUTSK REGION
por: O. A. Vorobiova, et al.
Publicado: (2012)

Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing
por: Xinchang Chen, et al.
Publicado: (2020)

TB and HIV Epidemiology and Collaborative Service: Evidence from Ethiopia, 2011–2015
por: Gelaw YA, et al.
Publicado: (2020)